CEO,Martin Gouldstone speaks to Vox Markets about the company’s six month interim results.

23 May 2024

Following the company’s recent announcement of their six month interim results, CEO Martin Gouldstone, speaks to Paul Hill of Vox Markets and discusses:

  • What the company does and the future growth in precision medicine
  • New application area in human longevity/ageing
  • Current client demand
  • Update on ONC’s commercialisation/turnaround strategy
  • Outlook & goals for FY25
  • Cash runway ahead

View the interview below: